Search research articles
Contact Us
Filters
Showing results (51-60 of 85) with videos related to
Page
of 9
Sort By:
British Journal of Haematology
|
November 9, 2018
Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes
Syed J Mehdi, Sarah K Johnson, Joshua Epstein, et al.
Haematologica
|
June 27, 2012
Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data
Sarah Waheed, Alan Mitchell, Saad Usmani, et al.
British Journal of Haematology
|
May 11, 2007
Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics
John D Shaughnessy, Jeffrey Haessler, Frits van Rhee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 7, 2007
Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling
Jeffrey Haessler, John D Shaughnessy, Fenghuang Zhan, et al.
Nature
|
June 24, 2008
IRF4 addiction in multiple myeloma
Arthur L Shaffer, N C Tolga Emre, Laurence Lamy, et al.
Lancet (London, England)
|
December 27, 2016
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
Brian G M Durie, Antje Hoering, Muneer H Abidi, et al.
Blood
|
May 22, 2008
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities
Bart Barlogie, Mauricio Pineda-Roman, Frits van Rhee, et al.
Haematologica
|
May 30, 2015
Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)
Rashid Khan, Madhav Dhodapkar, Adam Rosenthal, et al.
Blood Cancer Journal
|
May 13, 2020
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)
Brian G M Durie, Antje Hoering, Rachael Sexton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2012
Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1
Christoph J Heuck, Jackie Szymonifka, Emily Hansen, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 85) with videos related to
Sort By:
Page
of 9
British Journal of Haematology
|
November 9, 2018
Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes
Syed J Mehdi, Sarah K Johnson, Joshua Epstein, et al.
Haematologica
|
June 27, 2012
Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data
Sarah Waheed, Alan Mitchell, Saad Usmani, et al.
British Journal of Haematology
|
May 11, 2007
Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics
John D Shaughnessy, Jeffrey Haessler, Frits van Rhee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 7, 2007
Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling
Jeffrey Haessler, John D Shaughnessy, Fenghuang Zhan, et al.
Nature
|
June 24, 2008
IRF4 addiction in multiple myeloma
Arthur L Shaffer, N C Tolga Emre, Laurence Lamy, et al.
Lancet (London, England)
|
December 27, 2016
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
Brian G M Durie, Antje Hoering, Muneer H Abidi, et al.
Blood
|
May 22, 2008
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities
Bart Barlogie, Mauricio Pineda-Roman, Frits van Rhee, et al.
Haematologica
|
May 30, 2015
Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)
Rashid Khan, Madhav Dhodapkar, Adam Rosenthal, et al.
Blood Cancer Journal
|
May 13, 2020
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)
Brian G M Durie, Antje Hoering, Rachael Sexton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2012
Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1
Christoph J Heuck, Jackie Szymonifka, Emily Hansen, et al.
Page
of 9